Miriam-Rose Menezes Ph.D. Email & Phone Number

Philadelphia, PA, US

• In my role, I craft strategies for the design and execution of pre-clinical studies, driving the advancement of gene therapy candidates. I collaborate with cross-functional teams to evaluate and optimize vector.
• Designed and implemented automated plasmid DNA production platforms to meet pipeline demands and enhance product and process development.
• Reduced process bottlenecks by 60% through development and transfer of nanoplate-based HT-dPCR for Vg titer, enhancing in-process testing.
• Published two articles in peer-reviewed journals, contributing to the scientific community and enhancing personal and organizational reputation.
• Delivered oral presentations at two international conferences, showcasing research findings and fostering industry collaboration.
• Led and mentored interns as well as co-op students in high-throughput screening projects to optimize adeno-associated virus (AAV) production, refining existing processes.

New York, NY, US

• In my role, I facilitated collaborations with external institutes to optimize hit molecules for SAR and hit-to-lead conversion. I provided expertise and training to researchers on advanced techniques such as SPR.
• Designed, developed, and implemented high-throughput screening (HTS) of 400,000 small molecules using biochemical assays to propel oncology, COVID-19, and cardiovascular therapeutic discovery.
• Facilitated transition of hit molecules into lead optimization phase through effective collaboration and partnership with external research entities.
• Enhanced research capabilities by training fellow researchers in advanced validation techniques, significantly improving project throughput and accuracy.

Houston, Texas, US

• I initiated and spearheaded a collaborative effort with GSK to validate hits and optimize leads, paving the way for potential therapeutic advancements. I managed and curated CRISPR-Cas9 engineered cell lines and.
• Established a partnership with GSK, leading to pre-DePac collaboration for hit validation and lead optimization.
• Authored four peer-reviewed articles, contributing to scientific community's understanding of targeted cancer therapies.
• Presented research findings at three international conferences, showcasing expertise in cell-based assay development and molecular biology.

Worked in a team of six to: Provide consultancy services to strategize market entry for TMC Biotech Startups.Wrote patent drafts to protect IP for early stage TMC Biotech companies.

Houston, Texas, US

This internship provided me with the opportunity to gain insights into commercialization of life science technologies. I performed due diligence to determine feasibility of assets from pharmaceutical companies for further studies. I worked with one of the portfolio companies to determine the feasibility of repurposing a therapeutic compound for a novel.

New Haven, CT, US

• I conducted cutting-edge research using genetically engineered mouse models and cell culture systems to elucidate the mechanisms of tumorigenesis linked to patient-associated variants of DNA repair proteins. By.
• Authored three peer-reviewed publications, showcasing findings on base-excision repair protein variants and role in cancer.
• Presented research findings at multiple international conferences, highlighting lab's contributions to scientific community.
• Provided mentorship and hands-on training to junior researchers, ensuring rigorous scientific inquiry and project fidelity.

Omaha, Nebraska, US

I managed multi-departmental collaborations to demonstrate the mechanism by which the nucleotide pool cleansing enzyme, Inosine triphosphate pyrophosphates (ITPA) contributed to increased mutagenesis as well as adverse drug reactions in patients administered with base analogs as part of an immune-suppressive regimen.

Doctor Of Philosophy (Ph.D.), Cancer Research

Master Of Science (M.Sc.), Biophysics

Bachelor Of Science (B.Sc.), Microbiology And Biotechnology